Rezolute prices $100M stock offering led by Frazier Life Sciences
What's the deal? Rezolute, a late-stage metabolic disease company, has priced an underwritten offering of common stock and pre-funded warrants for gross proceeds of about $100 million. The financing, led by Frazier Life SciencesDealroom has a profile for this one. Try Dealroom → with participation from new and existing funds, is expected to close on or about November 16, 2026.
The terms: Rezolute is selling 22,040,976 shares at $3.87 each, plus pre-funded warrants for up to 3,800,000 shares at $3.869 apiece. Morgan Stanley, Guggenheim SecuritiesDealroom has a profile for this one. Try Dealroom →, and CantorDealroom has a profile for this one. Try Dealroom → are joint book-running managers.
Why now? The raise lands alongside a sharp shift in the company's clinical outlook. On the same day, Rezolute said its Phase 3 upLIFT study in tumour-related hyperinsulinism met its primary efficacy endpoint, with 13 participants meeting the responder criterion.
What's the endgame? Rezolute will use the proceeds, with existing cash, to fund commercialisation preparation for ersodetug, its antibody therapy for refractory hypoglycaemia caused by hyperinsulinism. The drug has been studied in clinical trials and used in real-world cases.
What could go wrong? Ersodetug remains investigational, and the company's latest filing targeted a BLA submission in mid-2027. Its congenital-HI Phase 3 sunRIZE trial missed its primary and key secondary endpoints; the FDA has encouraged a pre-BLA meeting but has not indicated whether the data would support approval.
The signal: This is a substantial repeat raise — Rezolute gathered about $90 million gross in April 2025 — extending funding into its next development stage while adding considerable potential share dilution.
Read more: marketscreener.com
Image credit: Generated with Gemini